An observational study on safety profile of ofloxacin and levofloxacin in treatment of acute exacerbation of chronic bronchitis

Abstract

Background COPD is predicted to be the third most common cause of death and chronic disability in the world by 2020. The term COPD encompasses several conditions. These include airflow obstruction with little reversibility, chronic bronchitis, emphysema, and small airways disease. Outcomes when hospitalized are poor, with 34% being re-admitted and 14% dying within 3 months. Aims and objectives To monitor, evaluate and compare the adverse effect profile of Ofloxacin and Ciprofloxacin in acute exacerbation of chronic bronchitis. Methods This was a prospective, observational study done in 200 patients of clinically diagnosed acute bronchitis in the department of pulmonology, SMC/GGH, Vijayawada. Newly diagnosed 200patients of acute bronchitis (from January 2017 to June 2017), pulmonology outpatient department, GGH, SMC, VJA of age 18–65 years of either gender who were prescribed either Levofloxacin (n = 100) or ofloxacin (OZP group, n = 100) and who gave written informed consent were enrolled. One group of the patients received Tab. Ofloxacin 400 mg BD and other group received Tab. Levofloxacin 500 mg OD for 7 days. The study duration was 6 months. Results In Ofloxacin group 63 patients reported ADRs out of which 40 are male and 23 are female. In Levofloxacin group, 19 patients reported ADR, of which 10 were men and 09 women (figure 1). Out of 63 ADRs in ofloxacin group 50 patients reported ADRs associated with CNS, 11patients reported ADRs associated with GIT & 02were associated with skin and its appendages. Out of 19 ADRs in levofloxacin group 10 patients reported ADRs associated with CNS, 08 patients reported ADRs associated with GIT & 01were associated with skin and its appendages (figure 2). Conclusion Even though, fluoroquinolones have excellent efficacy profile there are concerns about their safety. The present study concluded that no serious ADRs noted in both groups. But ofloxacin group of patients have shown increased incidence of ADRs associated with CNS especially Insomnia.

Authors and Affiliations

K Sankar

Keywords

Related Articles

Primary sclerosing cholangitis- a comprehensive review and update

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown etiology characterised by inflammation and fibrosis of the biliary tree. The aim of this review is to find out the cause, symptoms, a...

In vivo analgesic activity of petroleum ether extract of boswellia ovalifoliolata linn. Leaves

Boswellia ovalifoliolata Linn. (Family: Burseraceae) Leaves were extracted in petroleum ether (60°-80°C) to evaluate for centrally acting analgesic potential using tail immersion and peripheral pharmacological actions u...

Assessment of the drug utilization evaluation in Pediatric ambulatory care

Drug utilization evaluation is very important for antibiotics as they are widely used in hospitals and their inappropriate use in lead resistance. To regulate the rational use of antibiotics and promote the rational use...

To find the prevalence of HIV infection in pulmonary tuberculosis patients admitted in a secondary and tertiary care hospital of a rural area in Tamil Nadu – A retrospective study

Background Tuberculosis and HIV infections are the major health problems, especially in rural areas like Perambalur. Tuberculosis kills 1.8 million people per year worldwide. Unsuccessful treatment programmes for diseas...

In vitro studies on phytochemical analysis and antioxidant activity of Heliotropium indicum linn.

Objective The in vitro studies on phytochemical analysis and antioxidant activity of Heliotropium indicum Lin. (Boraginaceous) was evaluated by different assaying. Methods The in vitro antioxidant activity was evaluated...

Download PDF file
  • EP ID EP648128
  • DOI -
  • Views 59
  • Downloads 0

How To Cite

K Sankar (2019). An observational study on safety profile of ofloxacin and levofloxacin in treatment of acute exacerbation of chronic bronchitis. International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP), 8(2), 131-136. https://europub.co.uk/articles/-A-648128